Evidence map›Paper›PMID 34901560›Full record

ArticleBioactive materials2022

Bioactive extracellular matrix scaffolds engineered with proangiogenic proteoglycan mimetics and loaded with endothelial progenitor cells promote neovascularization and diabetic wound healing.

Siqi He, Tanaya Walimbe, Hongyuan Chen, Kewa Gao, Priyadarsini Kumar, Yifan Wei, Dake Hao, Ruiwu Liu, Diana L Farmer, Kit S Lam and 3 more

Open access · goldAbstract read
In one paragraph

Article in Bioactive materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Siqi HeDepartment of Burns and Plastic Surgery, The Third Xiangya Hospital of Central South University, China.
Tanaya WalimbeDepartment of Biomedical Engineering, UC Davis, United States.
Hongyuan ChenDepartment of Surgery, UC Davis, United States.
Kewa GaoDepartment of Burns and Plastic Surgery, The Third Xiangya Hospital of Central South University, China.
Priyadarsini KumarDepartment of Surgery, UC Davis, United States.
Yifan WeiDepartment of Surgery, UC Davis, United States.
Dake HaoDepartment of Surgery, UC Davis, United States.
Ruiwu LiuDepartment of Biochemistry and Molecular Medicine, UC Davis, United States.
Diana L FarmerDepartment of Surgery, UC Davis, United States.
Kit S LamDepartment of Biochemistry and Molecular Medicine, UC Davis, United States.
Jianda ZhouDepartment of Burns and Plastic Surgery, The Third Xiangya Hospital of Central South University, China.
Alyssa PanitchDepartment of Surgery, UC Davis, United States.
Aijun WangDepartment of Surgery, UC Davis, United States.
University of California, Davis · USShriners Hospitals for Children - Northern California · USCentral South University · CN

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
NCI NIH HHS P30 CA093373
6 · The paper itself

Abstract

Diabetic ischemic wound treatment remains a critical clinical challenge. Neovascularization plays a significant role in wound healing during all stages of the tissue repair process. Strategies that enhance angiogenesis and neovascularization and improve ischemic pathology may promote the healing of poor wounds, particularly diabetic wounds in highly ischemic conditions. We previously identified a cyclic peptide LXW7 that specifically binds to integrin αvβ3 on endothelial progenitor cells (EPCs) and endothelial cells (ECs), activates vascular endothelial growth factor (VEGF) receptors, and promotes EC growth and maturation. In this study, we designed and synthesized a multi-functional pro-angiogenic molecule by grafting LXW7 and collagen-binding peptides (SILY) to a dermatan sulfate (DS) glycosaminoglycan backbone, named LXW7-DS-SILY, and further employed this multi-functional molecule to functionalize collagen-based extracellular matrix (ECM) scaffolds. We confirmed that LXW7-DS-SILY modification significantly promoted EPC attachment and growth on the ECM scaffolds

Indexed as

Diabetic ischemic woundECM scaffoldEndothelial progenitor cellsNeovascularizationWound healing

Identifiers

PMID34901560
PMCPMC8636679
OpenAlexW3200700101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.